Safety, Pharmacokinetics (PK) of AKT and MEK Combination

Clinical Trial ID NCT01138085

Rank	Title	Journal	Year	PubWeight™‹?›
1	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.	Oncotarget	2012	1.96
2	A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.	Cancer Discov	2012	1.87
3	PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.	PLoS One	2011	1.80
4	NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.	Oncogene	2012	1.15
5	Targeting the RAS oncogene.	Expert Opin Ther Targets	2013	1.02
6	KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.	PLoS One	2012	0.96
7	The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.	Cancer Biol Ther	2011	0.89
8	Discovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical Modeling.	PLoS Comput Biol	2015	0.84
9	Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.	Oncotarget	2014	0.78
10	MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy.	Drug Des Devel Ther	2015	0.77